Project Grant R01CA316800
Award Date 8/12/26
Completion Date 7/31/31
Dollars Obligated $636K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- The National Cancer Institute awarded the Regents of the University of California, San Francisco $421,685 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop hyperpolarized 13C MRI as a biomarker for predicting immunotherapy response in cancer patients. The project addresses a clinical gap in immunotherapy monitoring: current imaging methods based on computed tomography and magnetic resonance imaging cannot reliably distinguish...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $640,466 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop covalent protein radiopharmaceuticals for targeted radionuclide therapy in cancer treatment. The project, funded through a Project Grant (R01CA309883), addresses a fundamental challenge in radiopharmaceutical design: balancing tumor uptake efficacy with safety by minimizing radiation exposure to normal...
- The National Cancer Institute of the Department of Health and Human Services awarded The Regents of the University of California, San Francisco $679,290 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop hyperpolarized carbon-13 dual-agent MRI imaging techniques for quantitative assessment of prostate cancer aggressiveness and improved biopsy guidance. The project translates novel safe, non-radioactive hyperpolarized 13C molecular MRI methods...
- The National Cancer Institute awarded the Regents of the University of California, San Francisco $700,838 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and optimize magnetic resonance multi-tasking abdominal imaging (MT-AI2) and advanced non-coplanar planning methods for functional avoidance stereotactic body radiation therapy (FA-SBRT) in primary and secondary liver tumors. The project aims to reduce radiation-induced liver disease (RILD)...
- The National Cancer Institute awarded the University of California, Davis $409,141 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop contrast-enhanced perfusion CT imaging as an alternative to current liver radioembolization workup procedures. The project addresses imaging optimization for selective internal radiation therapy (SIRT), a catheter-based treatment for liver cancer using radioactive yttrium-90 microspheres. Current clinical practice...
- The National Cancer Institute awarded The Leland Stanford Junior University $593,557 on March 18, 2026, under CFDA 93.394 (Cancer Detection and Diagnosis Research) to develop magnetic resonance methods for measuring response to an emerging lipophilic cancer therapy, specifically BPM31510, a coenzyme Q10 lipid nanoemulsion formulation. The research addresses a critical gap in clinical translation: the lack of real-time measurement tools to assess tumor response to this therapeutic agent, which...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $636,345 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the molecular mechanisms of PI3K activation in cancer using biochemical assays and cryo-electron microscopy imaging. The project focuses on phosphoinositide 3-kinase alpha (PI3KA), one of the most frequently mutated proteins in cancer. Researchers will elucidate how receptor tyrosine kinases and RAS...
- The National Cancer Institute awarded the University of California, Los Angeles $640,956 on May 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an artificial intelligence-enhanced perfusion MRI imaging biomarker for predicting yttrium-90 microsphere distribution in radioembolization treatment of liver cancer. The project addresses the current limitation that determining how Y90 microspheres disperse in a tumor relies on labor-intensive tracking of...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $420,943 on August 6, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate alpha-particle radioimmunotherapy combined with antibody-drug conjugates for pancreatic ductal adenocarcinoma treatment. The work establishes an alkaline phosphatase placental-like 2 (ALPPL2)-directed therapy platform exploiting restricted ALPPL2 expression in pancreatic cancer to concentrate...
- The National Cancer Institute awarded the University of California, Berkeley $712,375 on April 1, 2026, through the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop the ADAPT PRO system, a single, digitally programmable radiofrequency system that enables magnetic resonance imaging of any nucleus independent of or simultaneously with others. The project runs through March 31, 2031, with work performed in Berkeley, California. The ADAPT PRO system addresses a technical...